

REMARKS

Claims 8-9, 14-5, 20-23, 30 and 31-34 are pending and rejected. Claims 1-5, 10-13, 18-19 and 24-29 have been cancelled without prejudice. Applicants reserve the right to prosecute subject matter of the canceled claims in subsequent patent applications.

New claim 31 has been added to recite the transgenic plant according to claim 20, wherein said bacterium is *Thermomonospora*. Support is in the specification on page 10, lines 6-7.

New claim 32 has been added to recite the transgenic plant according to claim 20, wherein wherein the endoglucanase is thermostable. Support for this amendment is in the specification on page 4, line 6.

New claim 33 has been added to recite a transgenic seed obtained from the plant of claim 20. Support is in the specification on page 7, lines 9-10.

New claim 34 has been added to recite a transgenic seed obtained from the plant of claim 20, wherein said seed comprises said nucleic acid. Support is in the specification on page 7.

No new matter has been added by this amendment.

Claim Rejections under 35 USC 112, second paragraph

Claim 30 would have been rejected under 35 USC 112, second paragraph, as allegedly lacking antecedent basis for "the microbial source". Claim 30 has been amended to recite "microorganism".

Claim Rejection under 35 USC 112, first paragraph

Claims 6-9, 14, 16-17, 19-23 and 30 are rejected under 35 USC 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventors had possession of the claimed invention at the time the application was filed.

Applicants respectfully disagree with this rejection.

The legal standard for meeting the written description requirement under section 112, first paragraph, is whether "the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111,1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed.

The patent application need not teach what is already known to those of ordinary skill in the art (*Hyatt v. Boone*, 146 F.3d 1348, 47 USPQ2d 1128(Fed. Cir. 1998) citing *In re Eltgroth*, 419 F.2d 918, 921, 164 USPQ 221, 223 (CCPA 1970).

Applicants respectfully disagrees with a statement in the Office Action on page 4 where it states: "the specification only teaches one nucleic acid encoding a fungal β -1,4-endoglucanases, and nucleic acid encoding a fungal β -1,4-endoglucanases from only one *Thermomonospora* species" (emphasis added). The specification specifically describes three endoglucanases from the bacteria, *Thermomonospora fusca*, E1, E2 and E5 on page 14 of the specification. Further, the references cited on page 15 describe additional endoglucanases (cellulases) from bacterial and fungal sources that were available to those of ordinary skill in the art at the time of the filing of this application.

The specification as filed provides references describing several bacterial and fungal endoglucanases known to those in the art at the time the application was filed. These endoglucanases were available to those in the art. In particular, on pages 14-15 there list several sources of "cellulase genes for transformation into plants". The specification lists the *T. fusca* E1, E2 and E5 genes in particular set forth in references (GeneBank Accession No. L20094, Jung et al.1993), GenBank Accession no. M73321, Ghangas et al., 1988; Lao et al., 1991; and GenBank Accession No. L01577; Collmer and Wilson, 1983; Lao et al. 1991, respectively. The specification continues and states, "other cellulase genes may be transformed into plants according to the present invention as well, including all of the cellulase genes disclosed in the following references: Collmer *et al.* (1983) Bio/Technology 1:594-601; Ghanges *et al.* (1988) Appl. Environ. Microbiol. 54:2521-2526; Wilson (1992) Crit. Rev. Biotechnol. 12:45-63; Jung *et al.*

(1993) Appl. Environ. Microbiol. 59:3032-3043; Lao et al. (1991) J. Bacteriol. 173:3397-3407; and Thomas *et al.*, "Initial Approaches to Artificial Cellulase Systems for Conversion of Biomass to Ethanol"; Enzymatic Degradation of Insoluble Carbohydrates, J.N. Saddler and M.H. Penner, eds., ACS Symposium Series 618:208-36, 1995, American Chemical Society, Washington, D.C. These include, but are not limited to, endoglucanases, exoglucanases, and β -D-glucosidases derived from microorganisms such as bacteria and fungi."

In particular, Wilson (1992, Crit. Rev. Biotechnology 12:45-63) on page 46, col. 1, describes two cellulase genes isolated from *Thermomonospora curvata* (subsequently reclassified as *T. fusca*); five different cellulase genes from *Microbispora bispora* (citing Waldron *et al.*) and one cellulase from the fungus *Streptomyces* and one cellulase from the *Micromonospora*. Within this reference on page 56, col. 2, the authors compare the recently cloned cellulases with previously discovered cellulases from the bacteria *Pseudomonas fluorescens*, *Cellulomonas fimi* endoglucanase and *Bacillus* cellulase.

Lao *et al.*, (1991) J. Bacteriol. 173:3397-3407 describes three endoglucanase genes from *T. fusci* (E2, E5 and N-terminal of E4).

Thomas *et al.*, (1995) ACS Symposium Series 618:208-236 describes cellulases isolated from a variety of sources such as the fungus, *Trichoderma reesei* and the bacteria *Acidothermus cellulolyticus* and *Thermotoga meapolitana* (page 209, 3rd paragraph). Further, on page 210, the article states: "more than 60 cellulolytic fungi have been reported . . . representing the soft-rot, brown-rot, and white-rot fungi" (citations omitted). Also a review of the literature found 46 unique bacterial producers of cellulases including the genera *Thermomonospora*, *Microbispora*, *Acidothermus*, *Pseudomonas*, *Therotoga*, *Erwinia*, and *Acetivibrio*.

Additionally, various genetic databases, such as Genbank, were available at the time of the filing of this patent application that listed known endoglucanase sequences. For example, endoglucanase genes were isolated and identified in the three fungi *Humicola insolens* (Genbank Accession no. X76046; published in Mol. Gen. Genet. (1994) 243:253-260); *Penicillium janthinellum* (Genbank Accession no. X89564; published in Curr. Genet. (1996) 29:490-495); and *Hypocrea jecorina* (Genbank

Accession no. Z33381; published in Mol. Microbial. (1994) 13:219-228) (copies attached as Exhibits 1-3).

Given all these references and sources of endoglucanases from fungi or bacteria, one of ordinary skill in the art would be able to identify other sources of fungal and bacterial cellulases/endoglucanases beyond those of *T. fusci* used specifically in the examples of this application. It is not necessary in a patent application to describe information and facts known to those skilled in the art nor list every possible endoglucanase known at the time of the invention. The application as filed provides sufficient written description to identify other endoglucanases from bacteria and fungi to those of ordinary skill in the art.

Applicants submit these remarks and amendments overcome this rejection and request its withdrawal.

Claim Rejection under 35 USC 112, first paragraph

Claims 6-9, 14, 16-17, 19-23 and 30 are rejected under 35 USC 112, first paragraph, as allegedly not enabled by the specification for all β -1,4-endoglucanases. The specification is considered enabled for *T. fusca* β -1,4-endoglucanase.

Applicants respectfully disagree with this rejection.

Enablement of a disclosure "is not precluded by the necessity for some experimentation such as routine screening." In re Wands, 858 F.2d 731, 736-7 (Fed. Cir. 1988) (citations omitted). The experimentation necessary must not be undue. Id. At 737. Undue experimentation is experimentation that would require a level of ingenuity beyond what is expected from one of ordinary skill in the field. Fields v. Conover, 170 USPQ 276, 279 (CCPA 1971). The factors that can be considered in determining whether an amount of experimentation is undue have been listed in Wands, 858 F.2d at 737. Among these factors are: the amount of effort involved, the guidance provided by the specification, the presence of working examples, the amount of pertinent literature and the level of skill in the art. The test for undue experimentation is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine. Id.

The relevant inquiry for determining whether the scope of the claims is commensurate with the specification is “whether the scope of enablement provided to one of ordinary skill in the art by the disclosure is such as to be commensurate with the scope of protection sought by the claims.” In re Moore, 439 F.2d 1232, 1236 (CCPA 1971) (emphasis added). “A patent need not teach, and preferably omits, what is well known in the art.” Hybridtech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 231 USPQ 81 (Fed. Cir. 1986), cet. Denied, 480 U.S. 947 (1987).

While predictability of the art can be considered in determining whether an amount of experimentation is undue, mere unpredictability of the result of the experiment is not a consideration. Indeed, the Court of Customs and Patent Appeals has specifically cautioned that the unpredictability of the result of an experiment is not a basis to conclude that the amount of experimentation is undue (see In re Angstadt, 190 USPQ 214 (CCPA 1976)).

Enablement doesn’t require detailed description of every possible embodiment.

There is no requirement in section 112, first paragraph, that the specification provide a detailed description of every possible embodiment covered by the claims. The Examiner is respectfully referred to the controlling opinion in In re Goffe, 191 USPQ 429, 431 (1976), which makes clear that a claim may cover embodiments not actually reduced to practice prior to the filing date of the application:

For all practical purposes, the Board would limit appellant to claims involving the specific materials disclosed in the examples, so that a competitor seeking to avoid infringing the claims would merely have to follow the disclosure in the subsequently-issued patent to find a substitute. However, to provide effective incentives, claims must adequately protect inventors. To demand that the first to disclose shall limit his claims to what he has found will work or to materials which meet the guidelines specific for “preferred” materials in a process . . . would not serve the constitutional purpose of promoting progress in the useful arts.

The claimed method calls for integration into plant cells of a DNA construct encoding a β -1,4-endoglucanase. The regulatory regions instruct the plant cell to

transcribe the region of the DNA coding for the endoglucanase. The critical aspect of the method is not the nature of the endoglucanase, but rather the use of appropriate regulatory sequences which would function in the host plant cells to express the coding sequence. By using appropriate regulatory sequences, endoglucanases can be produced in plants cells as exemplified by the production of *T. fusca* endoglucanase.

In line with the holding in Goffe, supra, it does not serve the constitutional purpose of promoting progress in the useful arts if others may take Applicants' example of production of the *T. fusca* endoglucanase in a plant cell and substitute the coding sequence from a structural gene for another endoglucanase to obtain expression of that endoglucanase. The Examiner is fully aware that substituting one structural gene for another in an expression cassette is within the knowledge of one of ordinary skill in the art and does not require "undue experimentation."

As admitted by the Examiner in the Advisory Action, "plant promoters are described in the literature within the full scope of the claims".

Many bacterial and fungal endoglucanases are described in the reference cited in the specification. The specification also describes how to make expression cassettes and express an exemplary endoglucanase in the plastid of plant cells. Given the descriptions in the specification, one of ordinary skill in the art would be able to substitute an endoglucanase of *T. fusci* and replace it with another endoglucanase from a different fungal or bacterial source without any undue experimentation.

The presently claimed invention is NOT to the endoglucanase genes themselves, but to plants transgenically modified to express microbial endoglucanases. Therefore, one need only describe samples of endoglucanases to enable those of skill in the art to produce the invention.

Applicants submit these remarks and amendments overcome this rejection and request its withdrawal.

CONCLUSION

Applicants point out that the above remarks and amendments overcome the rejections. Reconsideration of the application and allowance of all pending claims is earnestly solicited.

Should the Examiner wish to discuss any of the above in greater detail or deem that further amendments should be made to improve the form of the claims, the Examiner is invited to telephone the undersigned at the Examiner's convenience.


Respectfully submitted,



Mary Kakefuda
Attorney for Applicants
Registration No. 39,245
Telephone: 919-765-5071

Syngenta Biotechnology, Inc.
3054 E. Cornwallis Road
Research Triangle Park, NC 27709-2257

Date: April 24, 2006



Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

PubMed

OMIM

Books

My NCBI

[Sign In]

[Register]

Search

Nucleotide

 for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

GenBank

 Show

5

Send to

Range: from

begin

 to

end

Reverse complemented strand

 Features:

SNP

CDD

MGC

HPRD

1: X76046. Reports H.insolens CMC3 m...[gi:505194]

Links

• Features

• Sequence

LOCUS

HICMC3

1239 bp

DNA

linear

PLN 18-APR-2005

DEFINITION

H.insolens CMC3 mRNA for endoglucanase.

ACCESSION

X76046

VERSION

X76046.1

GI:505194

KEYWORDS

CMC3 gene; endoglucanase.

SOURCE

Humicola insolens

ORGANISM

Humicola insolens

Eukaryota; Fungi; Ascomycota; mitosporic Ascomycota; Humicola.

REFERENCE

1 (bases 1 to 1239)

AUTHORS

Dalboege,H. and Hansen,H.P.H.

TITLE

A novel method for efficient expression cloning of fungal enzyme genes

JOURNAL

Mol. Gen. Genet. 243 (3), 253-260 (1994)

PUBMED

8190078

REFERENCE

2 (bases 1 to 1239)

AUTHORS

Dalboege,H.

TITLE

Direct Submission

JOURNAL

Submitted (04-NOV-1993) H. Dalboege, Manager GeneExpress, Novo Nordisk A/S, Symbion, Fruebjergvej 3, 2100 Copenhagen OE, DENMARK

FEATURES

Location/Qualifiers

source

1..1239

/organism="Humicola insolens"

/mol_type="genomic DNA"

/db_xref="taxon:34413"

gene

16..1182

/gene="CMC3"

CDS

16..1182

/gene="CMC3"

/EC_number="3.2.1.4"

/note="cellulase"

/codon_start=1

/product="beta-1,4 endoglucanase"

/protein_id="CAA53631.1"

/db_xref="GI:505195"

/db_xref="GOA:Q12624"

/db_xref="InterPro:IPR000254"

/db_xref="InterPro:IPR001547"

/db_xref="UniProtKB/Swiss-Prot:Q12624"

/translation="MKHSVLAGLFATGALAQQGAWQQCGGVGFSGSTSCVSGYTCVYLNDWYSQCQPQPTTLRRTTTTPGATSTTRSAPAATSTTPAKGKFKWFGINQSCAEFGKGEYPGLWGKHFTFPSTSSIQTHINDGFNMFRVAFSMERLAPNQLNAAFDANYLRNLTETVNFITGKGKYAMLDPHNFGRIYERIIIDKAAFASFFTKLATHFASNPLVVFDTNNEYHDMDQQLVFDLNLQAAIDAIRAAGATSQYIMVEGNSWTGAWTWNVTNNLAALRDPENKLVYQMHHYLDSDSGSGTSTACVSTQVGLQRVIGATNWLQRQNGKVGLLGEFAGGANSVCQQAIEGMLTHLQENSVDVWTGALWWAGGPWWGDYIYSFEPSPSIGYTYNSSLKKYVP"

seq_peptide16..63
/gene="CMC3"

ORIGIN

1

ctgaacacta

ttaccatgaa

gcacagtgtc

cttgccggtc

tcttcgcgac

tggagcgtc

61

gcccagggcg

gtgcatggca

gcagtgtggt

ggcgttggct

tctcgggctc

tacgtcctgt

121

gtgtccggtt

acacgtgcgt

gtacttgaac

gactggtaca

gccaatgcca

gccgcagccg

181

acgacgttac

ggacaacaac

aacgccaggg

gcaacatcga

caacaaggtc

agccccggct

241

gccacttcaa

ccactccggc

caagggcaag

ttcaagtgg

ttggcatcaa

ccagtcctgc

301

gctgagttcg

gcaagggaga

gtatcccggg

ctatggggca

agcactttac

cttccccctg

361

acgtcgtcga

ttcagacgca

catcaatgac

ggcttcaaca

tgttccgcgt

ggccttctca

421

atggagcggc

tggcacccaa

ccagctgaac

gccgcgttcg

atgccaaacta

cctccgaaac

481

ctgactgaga

ccgtcaattt

catcacgggc

aagggaaggt

atgcgatgct

tgacccccac

541

aacttcggcc

gctattatga

gagaatcatc

acggacaagg

ccgccttcgc

cagcttcttc

601

accaagctgg

ccacgcactt

cgcgtcgaac

cctcttgctg

tctttgacac

caacaacgag

661

taccacgaca

tggaccagca

gctcgtcttc

gatctcaacc

aggctgccat

cgacgccatc

721

cgcgccgcgg

gtgctacgtc

gcagtacatc

atggtcgagg

gcaactcgtg

gaccggggcg

781

tggacgtgga

acgtgaccaa

caacaacttg

gcggcgctac

gcgaccggga

gaacaagctg

841

gtgtaccaga

tgcatcagta

cctcgactcg

gacgggtccg

gcacgagcac

ggcctgcgtc

901

agcaccacag

tcggccttca

gcgcgtcatt

ggcgcgacca

actggctcag

gcaaaacggc

961

aaggttggac

tgctcggcga

gttcgccggc

ggcgccaact

cggtttgcca

gcaggccatt

1021

gagggcatgc

tcacccacct

ccaggagaat

agcgatgtct

ggacaggtgc

gctctggtgg

1081

gcgggaggcc

cgtggtgggg

tgactatata

tactcgtttg

aacctccttc

gggtattggc

1141

tacacctact

acaattccct

tctcaagaaa

tacgtgccat

aggtgctata

aagaccgtgg

1201

tcctgactca

agagggtttg

acaggacgca


gccctgagg

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jan 30 2006 12:09:03

BEST AVAILABLE COPY

Exhibit 2



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Nucleotide

My NCBI

[Sign In] [Register]

OMIM

Books

Search

Nucleotide

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

GenBank

Show

5

Send to

Range: from

begin

to

end

Reverse complemented strand

Features:

☐ SNP

☐ CDD

☒ MGC

☒ HPRD

☐

☐ 1: X89564. Reports P.janthinellum mR...[gi:984165]

Links

• Features

• Sequence

LOCUS PJEGL2 1373 bp mRNA linear PLN 13-SEP-1996
DEFINITION P.janthinellum mRNA for endoglucanase2.
ACCESSION X89564
VERSION X89564.1 GI:984165
KEYWORDS egl2 gene; endo-1,4-beta-glucanase; endoglucanase 2.
SOURCE Penicillium janthinellum
ORGANISM Penicillium janthinellum
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Penicillium.
REFERENCE 1 (bases 1 to 1373)
AUTHORS Mernitz,G., Koch,A., Henrissat,B. and Schulz,G.
TITLE Endoglucanase II (EGII) of Penicillium janthinellum: cDNA sequence,
heterologous expression and promotor analysis
JOURNAL Curr. Genet. 29 (5), 490-495 (1996)
PUBMED 8625430
REFERENCE 2
AUTHORS Mernitz,G., Koch,A., Henrissat,B. and Schulz,G.
TITLE EndoglucanaseII of Penicillium janthinellum-sequence, heterologous
expression and promoter analysis
JOURNAL Unpublished
REFERENCE 3 (bases 1 to 1373)
AUTHORS Mernitz,G.
TITLE Direct Submission
JOURNAL Submitted (12-JUL-1995) G. Mernitz, Institut fuer Mikrobiologie,
Max-Reimann-Strasse 16, D 14532 Kleinmachnow, FRG
FEATURES Location/Qualifiers
source 1..1373
/organism="Penicillium janthinellum"
/mol_type="mRNA"
/strain="Biourge IMET 43733 (C41)"
/db_xref="taxon:5079"
/chromosome="3"
/clone_lib="Lambda ZAPII"
gene 1..1373
/gene="egl2"
CDS 1..1233
/gene="egl2"
/EC_number="3.2.1.4"
/codon_start=1
/product="endoglucanase 2"
/protein_id="CAA61740.1"
/db_xref="GI:984166"
/db_xref="GOA:Q12665"
/db_xref="UniProtKB/TrEMBL:Q12665"
/translation="MMAQDKRTLALLALGGSALGQQTAWGQCGGQGTGATTCVSGY"

BEST AVAILABLE COPY

YCSFQNNWYSQCLPGAASTTSTSTTTTTVYSTTLKTTTSSSTSSAPTGKVRFAGVNIA
GFDFGVVTSQTQDLSQVVDDESVDGVNQMSHFVNADTFNIFRLPTGWQFIVNNNLGGS
DSNNFGKYEQVGSGLSLSGAYCIVDIHNYARWNGGVIGQGGPTDDQFISLWTQLATHY
KSNSRVIFGIMNEPHDLNIATWAATVQKTVTAIRNTGATSQMILLPGTDYTSANFIE
NGSGAALLPVTNPDGSTTNLIFDVHKYLDSDNSGTHAECVTNNADAFNNLATWLRSNK
RQALLSETGGGNVQSCATYMCQQLDILNANSADVYLGWTSWSAGGFQASWNYVLTEVPV
NGVDQYLVQQCFVPKWKN"








ORIGIN

1 atgatggctc aggacaagcg cactctgttg gcactccttg cccttggcgg atccgcgcta
61 gggcagcaaa cggcttgggg acaatgtggt ggtcagggat ggactggggc aaccacatgt
121 gtgtctgggt actactgctc cttccagaac aatttggtact ctcaagtgcct tcctggcgcg
181 gccagcacta ctagtacctc caccactacc actaccgtgt actcaaccac gttaaagacg
241 acgacgactt cgtcaacttc ttccgcgcgc acaggcaaag tacgatttgc tgggtgtcaac
301 attgccggct tcgacttttg cgtggtgaca agtgggtactc aggacctgtc tcagggtcgtc
361 gatgagtccg tggacggtgt caaccagatg tcacacttcg tcaacgcgga taccttcaac
421 attttccgcc tgccgactgg atggcagttc attgtcaaca acaaccttgg cggttctctc
481 gactcgaaca actttggcaa gtatgaacaa gttggttcag ggctgtctct ctctggcgct
541 tattgtattg ttgatattca caactacgcc cgctggaacg gtggcggttat cggacaaggc
601 ggtccaaccg atgaccaatt catcagcctc tggacgcaat tggccactca ctacaagagt
661 aacagcaggg ttatcttttg catcatgaac gagcccatg atctcaacat cgcaacctgg
721 gctgccacag tccagaagac tgtgactgcg atcagaaaca ctggagccac gtctcagatg
781 attctgctcc ctggtacgga ctacaccagc gctgccaact tcattgagaa tggctccggt
841 gcagcgctcc taccggtgac caacccgat ggatccacca cgaacctgat ctttgatgtt
901 cacaagtacc tggatagtga caacagcggc acccacgccg agtgcgtgac caacaatgcc
961 gacgccttca acaatcttgc aacctggctg cgctcaaaca agagacaggc tctgctttcc
1021 gagactggtg gcggcaacgt ccaaagttgt gccacttaca tgtgccagca gcttgatctc
1081 ctcaatgcaa attctgatgt ctacctcggc tggacctctt ggagcgctgg aggcttccag
1141 gcctcttgga actatgtcct gactgaagtc ccagtcaatg gtgttgatca ataccttgtc
1201 caacagtgct tcgtcccaa gtggaagaac tgagcgctgg tagactggtc atgtatggat
1261 ccgattttgc tacttagaga aggaatctcc tcagttagt gcttttgagt ctggacaggc
1321 tggacttgaa cagttaggca atataattct agcaccactc ttatgatcaa aaa

BEST AVAILABLE COPY

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jan 30 2006 12:09:03



My NCBI
[Sign In] [Register]

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search

Nucleotide

 for

Go

Clear

Limits Preview/Index History Clipboard Details

Display

GenBank

 Show

5

 Send to

Range: from

begin

 to

end

☐ Reverse complemented strand Features: ☐ SNP ☐ CDD ☒ MGC ☒ HPRD ☐

1: Z33381. Reports T.reesei (QM9414)...[gi:485863]

Links

- Features
- Sequences

LOCUS TRGE14BG 1124 bp DNA linear PLN 26-JUN-1995

DEFINITION T.reesei (QM9414) gene for endo-1,4-beta-glucanase.

ACCESSION Z33381

VERSION Z33381.1 GI:485863

KEYWORDS endo-1,4-beta-glucanase; endo-1,4-beta-glucanase V.

SOURCE Hypocrea jecorina

ORGANISM Hypocrea jecorina
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
Hypocreomycetidae; Hypocreales; Hypocreaceae; Hypocrea.

REFERENCE 1 (bases 1 to 1124)

AUTHORS Saloheimo,A., Henrissat,B., Hoffren,A.M., Teleman,O. and Penttila,M.

TITLE A novel, small endoglucanase gene, egl5, from Trichoderma reesei isolated by expression in yeast

JOURNAL Mol. Microbiol. 13 (2), 219-228 (1994)

PUBMED 7984103

REFERENCE 2 (bases 1 to 1124)

AUTHORS Saloheimo,A.

TITLE Direct Submission

JOURNAL Submitted (05-MAY-1994) Saloheimo A., VTT Biotechnology and Food Research, Espoo, Finland

FEATURES Location/Qualifiers

source 1..1124
/organism="Hypocrea jecorina"
/mol_type="genomic DNA"
/db_xref="taxon:51453"

CDS join(76..144,205..270,333..926)
/codon_start=1
/product="endo-1,4-beta-glucanase V (EGV)"
/protein_id="CAA83846.1"
/db_xref="GI:485864"
/db_xref="GOA:P43317"
/db_xref="UniProtKB/Swiss-Prot:P43317"
/translation="MKATLVLGSLIVGAVSAYKATTTTRYDGGQEGACGCGSSSGAFPW
QLGIGNGVYTAAGSQALFDTAGASWCGAGCGKCYQLTSTGQAPCSCGTGGAAGQSII
VMVTNLCPPNNGNAQWCVPVGGTNQYGYSYHFDIMAQNEIFGDNVVVDFEPIACPGQAA
SDWGTCLCVGQQETDPTPVLGNDTGSTPPGSSPPATSSSPSGGGQQTLYGQCGGAGW
TGPTTCQAPGTCKVQNQWYSQCLP"

mat_peptide join(127..144,205..270,333..923)
/gene="egl5"
/product="endo-1,4-beta-glucanase V (EGV)"
/EC_number="3.2.1.4"
/function="hydrolysis of beta-1,4-linkages in cellulose and beta-glucan"
/note="Based on hydrophobic cluster analysis, EGV belongs

BEST AVAILABLE COPY

to family K of cellulases/xylanases and family 45 of glycosyl hydrolases together with EGB of Pseudomonas fluorescens and EGV of Humicola insolens."

exon76..144
/number=1

genejoin(127..144,205..270,333..923)
/gene="egl5"

intron145..204
/gene="egl5"
/number=1
/cons_splice=(5'site:NO, 3'site:YES)

exon205..270
/gene="egl5"
/number=2

intron271..332
/gene="egl5"
/number=2

exon333..923
/gene="egl5"
/number=3

misc_binding813..923
/gene="egl5"
/bound_moiety="fungal cellulose"

ORIGIN

1 cgtatctttac acaagggcgc tgcaactaat tgacttgatc ttccatctcg tgtcttgctt
61 gtaaccatcg tgaccatgaa ggcaactctg gttctcggtt ccctcattgt aggcgcggtt
121 tccgcgtaca aggccaccac cacggcaagt ctacatgctt ccaggtcaca acgtctgctc
181 aacaacctct aaccgaaagg ccagcgctac tacgatgggc aggagggtgc ttgcggatgc
241 ggctcgagct ccggcgcatc cccgtggcag gtaaaccatc gaccttgtct ggggcaaggg
301 actcgctcact tacatcctct ctctctctgc agctcggcat cggcaacgga gtctacacgg
361 ctgccggctc ccaggctctc ttcgacacgg ccggagcttc atggtgcggc gccgggtgcg
421 gtaaattgcta ccagctcacc tcgacgggcc aggcgccttg ctccagctgc ggcacgggag
481 gtgctgctgg ccagagcatt atcgctatgg tgaccaacct gtgcccgaac aatgggaacg
541 cgcagtgttg cccggtgggc ggcggcacca accaatacgg ctacagctac catttcgaca
601 tcatggcgca gaacgagatc ttggagaca atgtcgtcgt cgactttgag cccattgctt
661 gccccgggca ggctgcctct gactggggga cgtgcctctg cgtgggacag caagagacgg
721 atcccacgcc cgtcctcggc aacgacacgg gctcaactcc tcccgggagc tcgccgccag
781 cgacatcgtc gagtcggccg tctggcggcg gccagcagac gctctatggc cagtgtggag
841 gtgccggctg gacgggacct acgacgtgcc aggcgccagg gacctgcaag gttcagaacc
901 agtgggtact ccagtgctct ccttgagaag gcccaagata gccatgtctc tctagcattc
961 ttccggcgtc agtctgatct gcctatttaa tcaggtcagt caatatgtat ccagagataa
1021 taaattatgt atattatagc agtactgtat cattgctgct gtctgcctga cttcaatgct
1081 gcttccccta ttctcgttgc agtagcgttg gcgatatggg gcag

Disclaimer | Write to the Help Desk

NCBI | NLM | NIH

Jan 30 2006 12:09:03